With the popularity of deep neural networks (DNNs) in recent years, many researchers have proposed DNNs for the analysis of survival data (time-to-event data). These networks learn the distribution of survival times directly from the predictor variables without making strong assumptions on the underlying stochastic process. In survival analysis, it is common to observe several types of events, also called competing events.
View Article and Find Full Text PDFHere, we investigate the extent to which re-implementing a previously published algorithm for OCT-based drusen quantification permits replicating the reported accuracy on an independent dataset. We refined that algorithm so that its accuracy is increased. Following a systematic literature search, an algorithm was selected based on its reported excellent results.
View Article and Find Full Text PDFPurpose: To assess which visual function measures are most strongly associated with overall retinal drusen volume in age-related macular degeneration (AMD).
Methods: A total of 100 eyes (16 eyes with early AMD, 62 eyes with intermediate AMD, and 22 eyes from healthy controls) were recruited in this cross-sectional study. All subjects underwent several functional assessments: best-corrected visual acuity (BCVA), low-luminance visual acuity (LLVA), visual acuity (VA) measured with the Moorfields Acuity Chart (MAC-VA), contrast sensitivity with the Pelli-Robson test, reading speed using the International Reading Speed texts, and mesopic and dark-adapted microperimetry.
IEEE Trans Pattern Anal Mach Intell
September 2021
Over the last years, utilizing deep learning for the analysis of survival data has become attractive to many researchers. This has led to the advent of numerous network architectures for the prediction of possibly censored time-to-event variables. Unlike networks for cross-sectional data (used e.
View Article and Find Full Text PDFPurpose: To evaluate the secondary and exploratory outcomes of the Laser Intervention in Early Stages of Age-Related Macular Degeneration (LEAD) study, a 36-month trial of a subthreshold nanosecond laser (SNL) treatment for slowing the progression to late age-related macular degeneration (AMD) in its early stages.
Design: Multicenter, randomized, sham-controlled trial.
Participants: Two-hundred ninety-two patients with bilateral large drusen.